Lupus & antiphospholipid syndrome
Association of serum levels of galectin-9 and IP-10 with disease activation in lupus nephritis
Authors' conclusion
Serum Galectin-9 and IP-10 are elevated in active LN and show weak but statistically significant correlations with SLEDAI scores.
Study context
- Population
- Patients with biopsy-proven lupus nephritis (LN) fulfilling SLICC and 2019 EULAR/ACR criteria, antiphospholipid syndrome (APS) and primary Sjögren's disease (pSD) disease controls, and healthy volunteers59 LN patients
- Participants
- 31 / 28 / 36 / 17 / 61
- Exposure
- Serum galectin-9 and IP-10 in active LN vs inactive LN, APS, pSD and healthy controls
- Active LNn = 31
- Inactive LNn = 28
- APSn = 36
- pSDn = 17
- Healthy controlsn = 61reference
- Outcome
- Association of serum galectin-9 and IP-10 levels (enzyme-linked immunosorbent assay (ELISA)) with disease activity in LN
Methodological detailsbiomarker study, disease and healthy controls
- Biomarker study
- Disease and healthy controls
Main finding
As reported in the abstract
Serum galectin-9 and IP-10 levels
- Biomarker levels did not differ significantly among inactive LN, APS and pSD (p > 0.05)
- Active LN vs Inactive LN, APS, pSD and healthy controls: P ≤ 0.05
- Inactive LN, APS, pSD vs Healthy controls: P ≤ 0.05
Observational data: associations, not effects.
Further findings
Correlation with SLEDAI scores (weak but significant)
- Galectin-9: r
- 0.36
- Galectin-9: p
- P = 0.004
- IP-10: r
- 0.33
- IP-10: p
- P = 0.009
ROC: discrimination of active from inactive LN (moderate)
- AUC, galectin-9
- 0.695
- AUC, IP-10
- 0.658
Original publication
Association of serum levels of galectin-9 and IP-10 with disease activation in lupus nephritis. Lupus. Published 29 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →